Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 4/20 | 0.44 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4730800 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL8103777 | 0.67 | CRBN (0.32) | CRBN | |
| Succinimide SCHEMBL1600526 | 0.62 | — | — | |
| SCHEMBL17752777 | 0.62 | MEN1 (0.35) | — | |
| Succinimide SCHEMBL8361206 | 0.62 | CRBN (1.00) | CRBNKDM4ELMNACYP2C19TOP2A | |
| Succinimide SCHEMBL1326078 | 0.62 | CRBN (1.00) | CRBNKDM4ELMNACYP2C19TOP2A | |
| Succinimide SCHEMBL1466558 | 0.62 | — | — | |
| SCHEMBL5390716 | 0.62 | — | — | |
| Succinimide SCHEMBL10709037 | 0.60 | — | — | |
| Succinimide SCHEMBL284656 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304436-B2 | Pyrazolone derivatives as PDE4 inhibitors | NYCOMED GMBH (DE) | 2012-11-06 | — | — | US | claimed |
| EP-2148876-B1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-09-28 | — | — | EP | claimed |
| US-20100120757-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-13 | — | — | US | claimed |
| EP-2148876-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | Nycomed GmbH (DE) | 2010-02-03 | — | — | EP | claimed |
| WO-2008138939-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2008-11-20 | — | — | WO | claimed |
| CN-116057061-A | USP7 inhibitors | 首药控股(北京)股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-114907368-A | USP7 inhibitors | 首药控股(北京)股份有限公司 | 2022-08-16 | — | — | CN | disclosed |
| WO-2022048498-A1 | USP7 INHIBITOR | 首药控股(北京)股份有限公司 | 2022-03-10 | — | — | WO | disclosed |
| US-9090597-B2 | Pyrazolone derivatives as PDE4 inhibitors | TAKEDA GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-20140378509-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2014-12-25 | — | — | US | disclosed |
| US-8865745-B2 | Pyrazolone derivatives as PDE4 inhibitors | TAKEDA GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| EP-2402330-B1 | Pyrazolone-derivatives as PDE4 inhibitors | TAKEDA GMBH (DE) | 2013-06-26 | — | — | EP | disclosed |
| US-20130012544-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2013-01-10 | — | — | US | disclosed |
| US-8304436-B2 | Pyrazolone derivatives as PDE4 inhibitors | NYCOMED GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| EP-2508520-A1 | Pyrazolone-derivatives as PDE4 inhibitors | Nycomed GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
| EP-2402330-A1 | Pyrazolone-derivatives as PDE4 inhibitors | Nycomed GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| EP-2148876-B1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-09-28 | — | — | EP | disclosed |
| US-20100120757-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| EP-2148876-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | Nycomed GmbH (DE) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008138939-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120757-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE3A | CRBN 3586/4885PLCG1 1616/4885KDM4E 427/4885 |
| US-20130012544-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE5A | CRBN 3947/4885PLCG1 670/4885KDM4E 124/4885 |
| US-20140378509-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | CRBN 4086/4885PLCG1 643/4885KDM4E 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.